Johnson & Johnson’s RYBREVANT trial shows improved response rate
The OrigAMI-1 study is assessing the efficacy and safety of RYBREVANT combined with chemotherapy regimens mFOLFOX6 or FOLFIRI.
16 September 2024
16 September 2024
The OrigAMI-1 study is assessing the efficacy and safety of RYBREVANT combined with chemotherapy regimens mFOLFOX6 or FOLFIRI.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional migraine markets through 2033. The report covers an exhaustive study of the countries wherein the market is prevalent, leading players, current treatment options, and factors driving the market growth. Furthermore, the pipeline valuation analysis and information on the market’s unmet needs and opportunities will help in determining potential business possibilities.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional migraine markets through 2033. The report covers an exhaustive study of the countries wherein the market is prevalent, leading players, current treatment options, and factors driving the market growth. Furthermore, the pipeline valuation analysis and information on the market’s unmet needs and opportunities will help in determining potential business possibilities.
Give your business an edge with our leading industry insights.